Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) announced that its LIBERTY® Endovascular Robotic System won the Innovative Start-Up Award from Surgical Robotics Technology for 2026.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and is used at leading academic centers across NY, PA, FL, GA, MA, MI, and NC.
The company reports continued adoption and utilization since the full market release in early April, viewing the award as validation of LIBERTY’s role in advancing robotic-assisted endovascular care.
Microbot Medical (Nasdaq: MBOT) announced that a globally recognized academic health system headquartered in Pennsylvania is the first in the state to adopt the LIBERTY Endovascular Robotic System. This customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey.
Microbot Medical now has LIBERTY accounts spanning seven Eastern U.S. states, following its transition to full market release in the second quarter, and plans to expand sales to the West Coast. An agreement to expand access across certain U.S. federal healthcare systems, including those serving veterans and military patients, is intended to support accelerated adoption.
Microbot Medical (Nasdaq: MBOT) signed an agreement with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business vendor, to expand access to the LIBERTY Endovascular Robotic System across federal healthcare systems.
The LIBERTY System is expected to be added to Lovell’s Federal Supply Schedule in Q3 2026 and listed on major federal procurement platforms, potentially reaching over 2,000 government facilities, including VHA, MHS, and IHS sites.
Microbot Medical (Nasdaq: MBOT) announced that one of the largest healthcare systems in Michigan is the first in Michigan and the broader Midwest to adopt the LIBERTY Endovascular Robotic System. This follows the company’s first healthcare system customer in North Carolina.
The adoption supports Microbot’s full market release strategy and reflects growing interest in robotic peripheral endovascular procedures, a U.S. market of about 2.5 million annual procedures. LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for these procedures and recently received regulatory approval for sale in Israel.
Microbot Medical (Nasdaq: MBOT) announced its first North Carolina-based customer for the LIBERTY Endovascular Robotic System. This leading academic healthcare system, operating a multi-hospital network across the state, becomes the first user in the Southeast/Mid-Atlantic region and adds to a growing roster of adopting health systems.
Microbot Medical (Nasdaq: MBOT) received its first international regulatory approval for commercializing the LIBERTY Endovascular Robotic System in Israel.
The Israeli Ministry of Health’s AMAR Division clearance enables marketing in Israel and supports obtaining a Free Sale Certificate for submissions and commercial activities in additional global jurisdictions.
Microbot Medical (Nasdaq: MBOT) will host an analysts and investors conference call and webcast on Monday, May 18 at 3:00pm ET. The event will review progress of the Full Market Release of the LIBERTY Endovascular Robotic System and address recent misrepresentations from an unaffiliated third-party article.
Executives will be joined by current LIBERTY users Dr. Charles Briggs and Dr. Zachary Bercu, who will discuss real-world clinical experience and clarify statements previously attributed to them.
Microbot Medical (Nasdaq: MBOT) reported its first commercial revenue from the Limited Market Release of the LIBERTY Endovascular Robotic System in Q1 2026 and has now transitioned to Full Market Release.
By mid-Q2 2026, revenue already exceeded Q1 levels as LIBERTY adoption grew, with hospitals in six U.S. states and more than double the number of accounts since the Limited Market Release ended. The system is being used for diverse procedures, including PAE for BPH, GAE for chronic knee pain and Y-90 radioembolization for liver cancer.
Microbot Medical (Nasdaq: MBOT) reported commercial adoption of the LIBERTY Endovascular Robotic System across multiple accounts, including two sites that participated in the ACCESS-PVI pivotal trial. The company cited growing physician interest after its Full Market Release at SIR and will exhibit at GEST May 14–17, 2026.
Microbot also appointed Alon Tamir as VP Sales, EMEA to support international commercialization efforts.
Microbot Medical (Nasdaq: MBOT) appointed Alon Tamir as Vice President of Sales for EMEA to accelerate commercial readiness for the LIBERTY Endovascular Robotic System.
The company holds FDA clearance (Sept 2025), completed a Limited and Full Market Release in the U.S., and expects a CE mark by end of 2026; Europe procedure volume is cited at ~2.3 million peripheral endovascular procedures.